Cessatech continues to perform: Danish Biotech Weekly (38)
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
We have decades of experience in analyzing small and mid-cap stocks as well as disseminating this information to retail investors. With investment cases, we provide free information on investment opportunities within the segment of Nordic small and mid-caps companies for primarily a Nordic investing audience.
If you want to contact us directly, find contact details for the individual employee under Line Up.
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Curasight has received positive results from a Phase 2 study of uTRACE in aggressive brain cancer, validating the technology and
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
In May, the current CEO of Ekobot resigned from his position, causing turmoil and a falling share price. The company
Mdundo is guiding for strong growth for the 2023/24 financial year and remains on course for its long-term goals in
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.